Prospective Evaluation of Immunological Molecular-genetic Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab

  • End date
    Mar 31, 2023
  • participants needed
  • sponsor
    LMU Klinikum
Updated on 16 September 2021
lung cancer
chemotherapy regimen


This non-interventional single-center explorative biomarker study aims at longitudinal comprehensive characterization (molecular genetics, immunological, morphological, image-based and microbial features) of the patient (host) and tumor as well as changes during standard treatment and in case of recurrent disease in inoperable stage III non-small cell lung cancer (NSCLC). Comprehensive analysis will include peripheral blood cellular and humoral immunophenotyping, circulating tumor DNA and gut/saliva microbiota analyses. 18F-FDG-PET/CT before, 6 weeks, 6- and 12-months after chemoradiotherapy as well as daily in course of radiation treatment cone-beam-CT and/or MRI imaging are included for morphological analysis. This study will provide valuable information of predictive biomarkers in patients with stage III NSCLC treated with durvalumab maintenance treatment after concurrent chemoradiotherapy.


The study will enrol 40 patients with stage III inoperable non-small cell lung cancer (NSCLC) who received standard chemoradiotherapy followed by maintenance therapy with PD-L1 inhibition (durvalumab) according to the current European Medicines Agency (EMA) approval.

The oncological treatment is carried out according to the international standards of radiation oncology/medical oncology. These are implemented by the department of radiation oncology at the University Hospital Munich (LMU) in their SOPs. Therefore, all patients will be treated with concurrent platinum-based chemoradiotherapy followed by durvalumab maintenance treatment 12 months after the end of chemoradiotherapy at the department of radiation oncology (University Hospital Munich (LMU)). Comprehensive characterization of all patients includes immunophenotyping of peripheral blood mono-nuclear cells, ctDNA as well as gut/saliva microbiome analyses and will be performed before, after 15 fractions of radiotherapy, at the end of concurrent chemoradiotherapy as well as 3-, 6- and 12 months after start of durvalumab.

18F-FDG-PET/CT will be performed 5-10 d before start of radiotherapy, 6 weeks, 6 months,12 and 24 months after the end of chemoradiotherapy. Lung function will be assessed before start of radiotherapy, at the end and 6 weeks after chemoradiotherapy as well as 3-, 6- and 12, 18, 24 months after start of durvalumab.

Follow-up will be performed by the department of radiation oncology at the University Hospital Munich (LMU) according to the clinical SOPs.

Condition NSCLC, Stage III, Chemoradiation, Biological Markers, durvalumab, Chemotherapy, Chemoradiotherapy, Oncology
Treatment Non-interventional
Clinical Study IdentifierNCT05027165
SponsorLMU Klinikum
Last Modified on16 September 2021


Yes No Not Sure

Inclusion Criteria

Patient age 18 years
Histologically/cytologically confirmed diagnosis of non-small-cell lung cancer (NSCLC)
Patients with non-operable NSCLC in tumor stage III A/B/C after UICC 8
Eligible for platinum-based concurrent chemoradiotherapy followed by durvalumab maintenance treatment
No invasive carcinoma in the last five years
ECOG Performance Status 0-2
Lung function parameters (before or after bronchodilation): FEV1 1.0 L and/or DLCO-SB 40%
A maximum of two cycles of induction chemotherapy are permissible before start of chemoradiotherapy

Exclusion Criteria

Simultaneous participation in another clinical trial
Mixed histology of small-cell and non-small-cell lung cancer
Brain metastases confirmed by a contrast enhanced cMRI
Prior receipt of an immunotherapy or investigational medicinal product
Previous exposure to an anti-PD-1 or anti-PD-L1 antibody
Pneumonitis Grade 2 as a result of prior radio-/chemoradiotherapy
Patients with a non-active disease in the last 5 years can be included, but only after consultation with the responsible investigator of the study or his representative
Primary immunodeficiencies in previous history
Prior Interstitial lung disease (ILD)
Prior autoimmune disease
Previous organ transplantation with subsequent therapeutic immunosuppression
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note